Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.65 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.65 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.65 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.65 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine SCHEMBL2226523 | 0.93 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Adenosine SCHEMBL8023430 | 0.92 | ADORA3 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2028411 | 0.89 | SLC28A1 (0.65) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Adenosine SCHEMBL438282 | 0.87 | ADORA3 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Cytidine SCHEMBL3824955 | 0.85 | LMNA (0.69) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL3345043 | 0.84 | SLC28A1 (0.64) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Deoxyuridine SCHEMBL8012707 | 0.84 | DUT (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3LMNA | |
| Uridine SCHEMBL22129341 | 0.83 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Cytidine SCHEMBL16970937 | 0.81 | LMNA (0.59) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL4455604 | 0.81 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117106894-A | Application of NKRF in diagnosis and treatment of pathological heart reconstruction | 山东大学齐鲁医院 | 2023-11-24 | — | — | CN | disclosed |
| US-20220401555-A1 | NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT | CUREVAC AG (DE) | 2022-12-22 | — | — | US | disclosed |
| US-20210046179-A1 | COMPOSITION COMPRISING A COMPLEXED (m)RNA AND A NAKED mRNA FOR PROVIDING OR ENHANCING AN IMMUNOSTIMULATORY RESPONSE IN A MAMMAL AND USES THEREOF | CUREVAC AG (DE) | 2021-02-18 | — | — | US | disclosed |
| US-20200085942-A1 | NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT | CUREVAC AG (DE) | 2020-03-19 | — | — | US | disclosed |
| EP-3346005-A1 | NUCLEIC ACIDS OF FORMULA (I) (NUGLXMGNNV)A AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENT/ADJUVANT | CureVac AG (DE) | 2018-07-11 | — | — | EP | disclosed |
| EP-2548960-B1 | NUCLEIC ACIDS COMPRISING FORMULA (NUGIXMGNV)A AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS/ADJUVANT | CUREVAC AG (DE) | 2018-01-31 | — | — | EP | disclosed |
| EP-2762165-B1 | Composition comprising a complexed (m)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof | CUREVAC AG (DE) | 2017-08-09 | — | — | EP | disclosed |
| US-20170202957-A1 | COMPOSITION COMPRISING A COMPLEXED (m)RNA AND A NAKED mRNA FOR PROVIDING OR ENHANCING AN IMMUNOSTIMULATORY RESPONSE IN A MAMMAL AND USES THEREOF | CUREVAC AG (DE) | 2017-07-20 | — | — | US | disclosed |
| US-9572874-B2 | Composition comprising a complexed (M)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof | CUREVAC AG (DE) | 2017-02-21 | — | — | US | disclosed |
| US-20160250321-A1 | NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT | CUREVAC AG (DE) | 2016-09-01 | — | — | US | disclosed |
| US-9226959-B2 | Nucleic acids comprising formula (NuGlXmGnNv)a and derivatives thereof as immunostimulating agent/adjuvant | CUREVAC AG (DE) | 2016-01-05 | — | — | US | disclosed |
| EP-2176408-B9 | NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS | CUREVAC GMBH (DE) | 2015-11-11 | — | — | EP | disclosed |
| EP-2176408-B1 | NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS | CUREVAC GMBH (DE) | 2015-03-11 | — | — | EP | disclosed |
| EP-2762165-A2 | Composition comprising a complexed (m)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof | CureVac GmbH (DE) | 2014-08-06 | — | — | EP | disclosed |
| EP-2331129-B1 | COMPOSITION COMPRISING A COMPLEXED (M)RNA AND A NAKED MRNA FOR PROVIDING OR ENHANCING AN IMMUNOSTIMULATORY RESPONSE IN A MAMMAL AND USES THEREOF | CUREVAC GMBH (DE) | 2014-06-18 | — | — | EP | disclosed |
| EP-2548960-A1 | Nucleic acids comprising formula (NuGIXmGnNv)a and derivatives thereof as an immunostimulating agents/adjuvant | CureVac GmbH (DE) | 2013-01-23 | — | — | EP | disclosed |
| EP-2176408-A2 | NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS | Curevac GmbH (DE) | 2010-04-21 | — | — | EP | disclosed |
| WO-2010037539-A1 | COMPOSITION COMPRISING A COMPLEXED (M)RNA AND A NAKED MRNA FOR PROVIDING OR ENHANCING AN IMMUNOSTIMULATORY RESPONSE IN A MAMMAL AND USES THEREOF | CUREVAC GMBH (DE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009095226-A2 | NUCLEIC ACIDS OF FORMULA (I) (NUGLXMGNNV)A AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENT/ADJUVANT | CUREVAC GMBH (DE) | 2009-08-06 | — | — | WO | disclosed |